Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
OTCPK:ALPMY's Cash-to-Debt is ranked higher than
94% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. OTCPK:ALPMY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:ALPMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.07  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.69
OTCPK:ALPMY's Equity-to-Asset is ranked higher than
59% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. OTCPK:ALPMY: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:ALPMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.69  Med: 0.75 Max: 0.78
Current: 0.69
0.69
0.78
Interest Coverage 129.43
OTCPK:ALPMY's Interest Coverage is ranked higher than
51% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. OTCPK:ALPMY: 129.43 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:ALPMY' s Interest Coverage Range Over the Past 10 Years
Min: 60.32  Med: 611.15 Max: No Debt
Current: 129.43
Piotroski F-Score: 6
Altman Z-Score: 5.12
Beneish M-Score: -2.63
WACC vs ROIC
2.68%
18.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 16.31
OTCPK:ALPMY's Operating Margin % is ranked higher than
74% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. OTCPK:ALPMY: 16.31 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:ALPMY' s Operating Margin % Range Over the Past 10 Years
Min: 10.25  Med: 16.52 Max: 28.37
Current: 16.31
10.25
28.37
Net Margin % 15.01
OTCPK:ALPMY's Net Margin % is ranked higher than
78% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. OTCPK:ALPMY: 15.01 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:ALPMY' s Net Margin % Range Over the Past 10 Years
Min: 7.09  Med: 11.72 Max: 18.24
Current: 15.01
7.09
18.24
ROE % 15.39
OTCPK:ALPMY's ROE % is ranked higher than
75% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. OTCPK:ALPMY: 15.39 )
Ranked among companies with meaningful ROE % only.
OTCPK:ALPMY' s ROE % Range Over the Past 10 Years
Min: 6.52  Med: 11.13 Max: 17.28
Current: 15.39
6.52
17.28
ROA % 10.83
OTCPK:ALPMY's ROA % is ranked higher than
80% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. OTCPK:ALPMY: 10.83 )
Ranked among companies with meaningful ROA % only.
OTCPK:ALPMY' s ROA % Range Over the Past 10 Years
Min: 5.01  Med: 8.45 Max: 12.27
Current: 10.83
5.01
12.27
ROC (Joel Greenblatt) % 76.56
OTCPK:ALPMY's ROC (Joel Greenblatt) % is ranked higher than
93% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. OTCPK:ALPMY: 76.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:ALPMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 26.38  Med: 57.05 Max: 90.92
Current: 76.56
26.38
90.92
3-Year Revenue Growth Rate 7.00
OTCPK:ALPMY's 3-Year Revenue Growth Rate is ranked higher than
56% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. OTCPK:ALPMY: 7.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:ALPMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.1 Max: 75.1
Current: 7
0
75.1
3-Year EBITDA Growth Rate 25.40
OTCPK:ALPMY's 3-Year EBITDA Growth Rate is ranked higher than
77% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. OTCPK:ALPMY: 25.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:ALPMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.8 Max: 77.5
Current: 25.4
0
77.5
3-Year EPS without NRI Growth Rate 36.90
OTCPK:ALPMY's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. OTCPK:ALPMY: 36.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:ALPMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.3 Max: 55.4
Current: 36.9
0
55.4
» OTCPK:ALPMY's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ALPMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major  
Compare:TSE:4519, TSE:4578, TSE:4568, TSE:4528, HKSE:01093, MIL:REC, TSE:4151, BOM:500087, BOM:500302, TSE:4536, ISX:KLBF, SHSE:600436, XKRX:008930, SHSE:600867, SZSE:002422, TSE:2784, SZSE:002019, SZSE:002424, NSE:TORNTPHARM, TSE:9987 » details
Traded in other countries:YPH.Germany, 4503.Japan,
Headquarter Location:Japan
Astellas Pharma Inc is a drug manufacturing company with focus on oncology. It sells its pharmaceutical products across the globe.

Astellas Pharma is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements in order to strengthen its commercialization platforms.

Top Ranked Articles about Astellas Pharma Inc

Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology
U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
U.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia
Astellas Announces Wind-Down of Agensys Research Operations
U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia
The Astellas Oncology C3 Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

Ratios

vs
industry
vs
history
PE Ratio 16.24
ALPMY's PE Ratio is ranked higher than
76% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. ALPMY: 16.24 )
Ranked among companies with meaningful PE Ratio only.
ALPMY' s PE Ratio Range Over the Past 10 Years
Min: 8.65  Med: 16.98 Max: 104.4
Current: 16.24
8.65
104.4
PE Ratio without NRI 16.24
ALPMY's PE Ratio without NRI is ranked higher than
78% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. ALPMY: 16.24 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALPMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.65  Med: 16.98 Max: 104.45
Current: 16.24
8.65
104.45
Price-to-Owner-Earnings 15.40
ALPMY's Price-to-Owner-Earnings is ranked higher than
82% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.43 vs. ALPMY: 15.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALPMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.59  Med: 25.91 Max: 151.52
Current: 15.4
13.59
151.52
PB Ratio 2.22
ALPMY's PB Ratio is ranked higher than
61% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. ALPMY: 2.22 )
Ranked among companies with meaningful PB Ratio only.
ALPMY' s PB Ratio Range Over the Past 10 Years
Min: 1.27  Med: 2.07 Max: 3.37
Current: 2.22
1.27
3.37
PS Ratio 2.44
ALPMY's PS Ratio is ranked higher than
58% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. ALPMY: 2.44 )
Ranked among companies with meaningful PS Ratio only.
ALPMY' s PS Ratio Range Over the Past 10 Years
Min: 1.35  Med: 2.29 Max: 10.2
Current: 2.44
1.35
10.2
Price-to-Free-Cash-Flow 13.73
ALPMY's Price-to-Free-Cash-Flow is ranked higher than
77% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. ALPMY: 13.73 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALPMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.23  Med: 23.98 Max: 81.38
Current: 13.73
12.23
81.38
Price-to-Operating-Cash-Flow 11.48
ALPMY's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. ALPMY: 11.48 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALPMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.43  Med: 15.29 Max: 56.47
Current: 11.48
9.43
56.47
EV-to-EBIT 11.39
ALPMY's EV-to-EBIT is ranked higher than
80% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. ALPMY: 11.39 )
Ranked among companies with meaningful EV-to-EBIT only.
ALPMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.1  Med: 11.1 Max: 38.6
Current: 11.39
4.1
38.6
EV-to-EBITDA 9.00
ALPMY's EV-to-EBITDA is ranked higher than
82% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. ALPMY: 9.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALPMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.5  Med: 9 Max: 38.6
Current: 9
3.5
38.6
EV-to-Revenue 2.09
ALPMY's EV-to-Revenue is ranked higher than
65% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. ALPMY: 2.09 )
Ranked among companies with meaningful EV-to-Revenue only.
ALPMY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9  Med: 2 Max: 10.2
Current: 2.09
0.9
10.2
PEG Ratio 0.34
ALPMY's PEG Ratio is ranked higher than
95% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.89 vs. ALPMY: 0.34 )
Ranked among companies with meaningful PEG Ratio only.
ALPMY' s PEG Ratio Range Over the Past 10 Years
Min: 0.34  Med: 0.75 Max: 9.25
Current: 0.34
0.34
9.25
Shiller PE Ratio 23.71
ALPMY's Shiller PE Ratio is ranked higher than
75% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. ALPMY: 23.71 )
Ranked among companies with meaningful Shiller PE Ratio only.
ALPMY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 21.09  Med: 21.75 Max: 23.71
Current: 23.71
21.09
23.71
Current Ratio 2.18
ALPMY's Current Ratio is ranked lower than
56% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. ALPMY: 2.18 )
Ranked among companies with meaningful Current Ratio only.
ALPMY' s Current Ratio Range Over the Past 10 Years
Min: 2.12  Med: 2.6 Max: 5.5
Current: 2.18
2.12
5.5
Quick Ratio 1.76
ALPMY's Quick Ratio is ranked lower than
52% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. ALPMY: 1.76 )
Ranked among companies with meaningful Quick Ratio only.
ALPMY' s Quick Ratio Range Over the Past 10 Years
Min: 1.72  Med: 2.18 Max: 5.17
Current: 1.76
1.72
5.17
Days Inventory 183.74
ALPMY's Days Inventory is ranked lower than
79% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. ALPMY: 183.74 )
Ranked among companies with meaningful Days Inventory only.
ALPMY' s Days Inventory Range Over the Past 10 Years
Min: 119.18  Med: 141.16 Max: 196.01
Current: 183.74
119.18
196.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.11
ALPMY's Dividend Yield % is ranked higher than
70% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. ALPMY: 1.11 )
Ranked among companies with meaningful Dividend Yield % only.
ALPMY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.85  Med: 2.46 Max: 4.39
Current: 1.11
0.85
4.39
Dividend Payout Ratio 0.16
ALPMY's Dividend Payout Ratio is ranked higher than
81% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 0.16 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ALPMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.48 Max: 0.85
Current: 0.16
0.16
0.85
3-Year Dividend Growth Rate 8.00
ALPMY's 3-Year Dividend Growth Rate is ranked higher than
53% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. ALPMY: 8.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ALPMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 7.2 Max: 52.5
Current: 8
1.3
52.5
5-Year Yield-on-Cost % 1.55
ALPMY's 5-Year Yield-on-Cost % is ranked higher than
70% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. ALPMY: 1.55 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALPMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.18  Med: 3.4 Max: 6.07
Current: 1.55
1.18
6.07
3-Year Average Share Buyback Ratio 2.50
ALPMY's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. ALPMY: 2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALPMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.8  Med: 2.5 Max: 0
Current: 2.5
-12.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 10.14
ALPMY's Price-to-Net-Current-Asset-Value is ranked lower than
62% of the 474 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.23 vs. ALPMY: 10.14 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALPMY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.2  Med: 4.81 Max: 10.14
Current: 10.14
2.2
10.14
Price-to-Tangible-Book 4.39
ALPMY's Price-to-Tangible-Book is ranked lower than
57% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. ALPMY: 4.39 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALPMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.46  Med: 2.62 Max: 4.87
Current: 4.39
1.46
4.87
Price-to-Intrinsic-Value-Projected-FCF 1.26
ALPMY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
76% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. ALPMY: 1.26 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALPMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.15  Med: 1.79 Max: 2.37
Current: 1.26
1.15
2.37
Price-to-Median-PS-Value 1.07
ALPMY's Price-to-Median-PS-Value is ranked higher than
54% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. ALPMY: 1.07 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALPMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.61  Med: 1 Max: 4.15
Current: 1.07
0.61
4.15
Price-to-Peter-Lynch-Fair-Value 0.65
ALPMY's Price-to-Peter-Lynch-Fair-Value is ranked higher than
90% of the 183 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. ALPMY: 0.65 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ALPMY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.16 Max: 5.89
Current: 0.65
0.42
5.89
Price-to-Graham-Number 1.78
ALPMY's Price-to-Graham-Number is ranked higher than
60% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.97 vs. ALPMY: 1.78 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ALPMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.91  Med: 1.62 Max: 2.63
Current: 1.78
0.91
2.63
Earnings Yield (Greenblatt) % 8.76
ALPMY's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. ALPMY: 8.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALPMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 9 Max: 24.4
Current: 8.76
2.6
24.4
Forward Rate of Return (Yacktman) % 35.84
ALPMY's Forward Rate of Return (Yacktman) % is ranked higher than
90% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. ALPMY: 35.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALPMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.3  Med: 9.7 Max: 36.8
Current: 35.84
-10.3
36.8

More Statistics

Revenue (TTM) (Mil) $11,754.17
EPS (TTM) $ 0.84
Beta0.39
Short Percentage of Float0.00%
52-Week Range $11.82 - 15.22
Shares Outstanding (Mil)2,030.66 (ADR)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}